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Perfusion MR Imaging in Gliomas: 
Comparison with Histologic Tumor Grade
Objective: To determine the usefulness of perfusion MR imaging in assessing
the histologic grade of cerebral gliomas. 
Materials and Methods: In order to determine relative cerebral blood volume
(rCBV), 22 patients with pathologically proven gliomas (9 glioblastomas, 9
anaplastic gliomas and 4 low-grade gliomas) underwent dynamic contrast-
enhanced T2*-weighted and conventional T1- and T2-weighted imaging. rCBV
maps were obtained by fitting a gamma-variate function to the contrast material
concentration versus time curve. rCBV ratios between tumor and normal white
matter (maximum rCBV of tumor / rCBV of contralateral white matter) were calcu-
lated and compared between glioblastomas, anaplastic gliomas and low-grade
gliomas.
Results: Mean rCBV ratios were 4.90° 1.01 for glioblastomas, 3.97° 0.56
for anaplastic gliomas and 1.75° 1.51 for low-grade gliomas, and were thus sig-
nificantly different; p < .05 between glioblastomas and anaplastic gliomas, p < .05
between anaplastic gliomas and low-grade gliomas, p < .01 between glioblas-
tomas and low-grade gliomas. The rCBV ratio cutoff value which permitted dis-
crimination between high-grade (glioblastomas and anaplastic gliomas) and low-
grade gliomas was 2.60, and the sensitivity and specificity of this value were
100% and 75%, respectively.
Conclusion: Perfusion MR imaging is a useful and reliable technique for esti-
mating the histologic grade of gliomas. 
liomas are the most common primary neoplasms of the brain (1), varying
histologically from low grade (relatively benign) to high grade (malig-
nant). Even a single tumor mass may be histologically heterogeneous,
and at biopsy their grade thus tends to be underestimated. For planning the optimal
treatment strategy and assessing prognosis, accurate histologic grading is essential, and
for this, vascular proliferation is an important criteria; in determining the histologic
grade of a glioma, the evaluation of tumor vascularity is therefore valuable (2 5).
Recent developments in perfusion MR imaging techniques have permitted the creation
of relative cerebral blood volume (rCBV) maps, leading to the qualitative and quanti-
tative assessment of tumor vascularity (6 14). These maps have helped in the assess-
ment of tumor grade and in targeting the site of biopsy (15, 16). Although a few stud-
ies have reported good correlation between rCBV and the histologic grade of gliomas
(5, 15, 16), no study-to the best of our knowledge-has assessed the sensitivity and
specificity of rCBV measurement for discriminating between high-grade and low-grade
tumors. 
The purpose of this study was to assess the relationship between rCBV and the histo-
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Glogic grade of gliomas and to determine the rCBV ratio
cutoff value which permitted discrimination between high-
grade and low-grade gliomas, and the sensitivity and speci-
ficity of this value.
MATERIALS AND METHODS
Patients 
We retrospectively investigated 24 consecutive patients
with gliomas who had undergone both conventional and
perfusion MR imaging during a four-year period. Two pa-
tients with pilocytic astrocytomas were excluded because
these tumors, classified as circumscribed astrocytomas, are
more benign than diffuse infiltrating gliomas and do not
usually progress to malignancy. Consequently, 22 patients
with diffuse infiltrating gliomas were included in this study.
Sixteen were male and six were female, and their ages
ranged from nine to 71 (mean, 41) years. The presence of
gliomas was confirmed by surgical resection (n = 16), or by
stereotactic biopsy (n = 6). All tumors were graded accord-
ing to the World Health Organization grading system (17);
there were four grade-2 astrocytomas, nine grade-3
anaplastic gliomas [anaplastic astrocytoma (n = 6), anaplas-
tic oligodendroglioma (n = 2), anaplastic oligoastrocytoma
(n = 1)], and nine grade-4 glioblastomas. Tumors were lo-
cated in the cerebral hemisphere in 14 cases, the basal gan-
glia in five, and the cerebellum in three.
MR imaging studies
MR examinations were performed on a Siemens 1.5-T
63SP system (Erlangen, Germany) using the following
imaging sequences: axial turbo spin-echo T2-weighted, axi-
al spin-echo T1-weighted, dynamic contrast-enhanced T2*-
weighted (for perfusion imaging), and axial postcontrast
T1-weighted. The imaging parameters were 3500/90 (repe-
tition time msec/echo time msec) for T2-weighted and
550/14 for pre- and postcontrast T1-weighted imaging. The
section thickness/gap was 5 6/1.5 1.8 mm and the ma-
trix was 200 256. 
For dynamic contrast-enhanced T2*-weighted imaging, a
conventional gradient-echo sequence (40/26, 10° flip an-
gle, 64 128 matrix, 5 6 mm slice thickness, 3.8 sec ac-
quisition time) was used. In order to include the largest sol-
id portion of the tumor on the basis of the findings of T1-
and T2-weighted imaging, 17 20 serial, single-section dy-
namic images were obtained. Within 5 seconds of the ac-
quisition of the first three images, a Gd-DTPA (Magnevist,
0.2 mmol/kg; Schering, Germany) or gadodiamide
(Omniscan, 0.2 mmol/kg; Nycomed, Norway) bolus was
administered manually via a forearm vein, followed by a
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Table 1. Relative Cerebral Blood Volume Ratios of 22 Patients with Gliomas
No Age Sex Location Pathologic diagnosis rCBV ratio
01 42 M L temporal Glioblastoma 4.00
02 51 M L basal ganglia Glioblastoma 3.95
03 51 F R temporal Glioblastoma 4.57
04 55 M R frontal Glioblastoma 5.63
05 48 M L temporal Glioblastoma 3.75
06 59 M L temporal Glioblastoma 4.14
07 47 M R frontal Glioblastoma 5.93
08 43 M L frontal Glioblastoma 5.89
09 51 M L occipital Glioblastoma 6.26
10 40 M L parietal Anaplastic astrocytoma  5.11
11 38 M R basal ganglia Anaplastic oligodendroglioma 4.56
12 28 F L frontal Anaplastic astrocytoma 3.67
13 71 F L cerebellar  Anaplastic oligoastrocytoma 4.15
14 15 M L frontal Anaplastic astrocytoma  3.40
15 56 M L basal ganglia Anaplastic oligodendroglioma 3.96
16 39 M R temporal Anaplastic astrocytoma  3.46
17 31 F L frontal Anaplastic astrocytoma  3.62
18 09 M R frontal Anaplastic astrocytoma  3.78
19 41 M R basal ganglia Astrocytoma 1.79 
20 56 F L parietal Astrocytoma 0.39 
21 14 F L cerebellar Astrocytoma 3.85 
22 47 M L cerebellar Astrocytoma 0.97 
Note. rCBV = relative cerebral blood volume, L = left, R = rightflush of 30 ml saline. After the initiation of bolus injection,
approxinatel, bosecs were required for imaging.
Generation of rCBV maps 
All dynamic MR images were transferred to a personal
computer via ethernet, and were evaluated with home
made software. For the creation of rCBV map, an expo-
nential relationship between relative signal reduction and
contrast material concentration was assumed. To fit a gam-
ma-variate function to the contrast material concentra-
tion versus time curve on a pixel-by-pixel basis, the non-
linear regression method was used (18, 19). The rCBV of
each pixel was then calculated by numerical integration
of the area under the concentration-time curve (i.e. rCBV
= C(t)dt) (20). Thus, increased signal intensity on the
rCBV map indicated increased rCBV, and vice versa.
Data analysis
On an rCBV map, a region-of-interest (ROI), including at
least 20 pixels, was placed in the solid portion of a tumor
for measurement of rCBV. This was measured at least
three times, and for further analysis, its maximum value
was chosen. An rCBV obtained by our method is not an
absolute quantity, and for this reason, results were normal-
ized by calculating rCBV ratio (i.e. maximum rCBV of a
tumor divided by that of white matter). The rCBV of white
matter was obtained by placing the ROI, including at least
20 pixels, in contralateral frontal and occipital (or parietal)
white matter, and averaging those rCBV values. In three
cases of cerebellar tumors, the ROI was placed in contralat-
eral central white matter.
To assess the relationship between rCBV ratio and histo-
logic tumor grade, we compared rCBV ratios between
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Fig. 1. Case 7: Glioblastoma in a 47-
year-old man.
A. Postcontrast T1-weighted image
shows a ring-enhancing necrotic tumor
in the right frontal lobe.
B. Relative cerebral blood volume
(rCBV) map shows high rCBV in the sol-
id portion of the tumor (arrow). The high-
er signal on the rCBV map represents a
higher rCBV. 
C. rCBV map shows the placement of
ROIs for measurement of rCBV in the
tumor (black circle) and in contralateral
frontal and parietal white matter (white
circles).
D. Signal intensity-time curves mea-
sured at ROIs in C show different pat-
terns of signal reduction between tumor
and normal white matter during the tran-
sit of contrast material. Remarkable re-
duction of signal intensity is noted in the
tumor compared to normal white matter,
suggesting tumor hypervascularity.
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using the Kruskal-Wallis and Mann-Whitney U tests. The
latter was also used for comparing rCBV ratios between
high-grade (glioblastomas and anaplastic gliomas) and low-
grade gliomas. To calculate the rCBV ratio cutoff value
which permits discrimination between high-grade and low-
grade gliomas, and the sensitivity and specificity of this
value, univariate discriminant analysis was used. For statis-
tical computation, an SPSS statistical software package
(SPSS, Chicago, Ill.) was employed, with the level of signif-
icance defined as p < .05. 
RESULTS
Table 1 summarizes the rCBV ratios of all tumors. These
were 3.75 6.26 (mean, 4.90 1.01) in glioblastomas (Fig.
1), 3.40 5.11 (mean, 3.97 0.56) in anaplastic gliomas
(Fig. 2), and 0.39-3.85 (mean, 1.75 1.51) in low-grade
gliomas (Fig. 3). The overall group difference in rCBV ra-
tios between these three tumor groups was statistically sig-
nificant (p < .01, using the Kruskal-Wallis test). Individual
group differences in rCBV ratios were also significant (p <
.05 between glioblastomas and anaplastic gliomas, p < .05
between anaplastic gliomas and low-grade gliomas, and p <
.01 between glioblastomas and low-grade gliomas, using
the Mann-Whitney U test) (Fig. 4). The rCBV ratios of
high-grade gliomas, including glioblastomas and anaplastic
gliomas, were 3.40 6.26 (mean, 4.44 0.93), and were
statistically significantly higher than those of low-grade
gliomas (p < .05, using the Mann-Whitney U test). The
Lee et al.
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Fig. 2. Case 15: Anaplastic oligoden-
droglioma in a 56-year-old man.
A. Postcontrast T1-weighted image
shows a strongly enhancing solid tumor
in the left basal ganglia.
B. Relative cerebral blood volume
(rCBV) map shows heterogeneously in-
creased rCBV in the tumor (arrow). 
C. rCBV map shows the placement of
ROIs for measurement of rCBV in the
tumor (black circle) and in contralateral
frontal and occipital white matter (white
circles).
D. Signal intensity-time curves mea-
sured at ROIs in C show different pat-
terns of signal reduction between tumor
and normal white matter, suggesting tu-
mor hypervascularity.
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tween high-grade (i.e. glioblastomas and anaplastic
gliomas) and low-grade gliomas was 2.60. The sensitivity
and specificity of this value were 100% (18/18) and 75%
(3/4), respectively.
DISCUSSION
Gliomas are the most common neoplasm of the brain,
and have a heterogeneous histologic spectrum from low-
grade astrocytomas to glioblastomas (1). In spite of im-
provements in the results of surgery, radiation therapy and
chemotherapy, the prognosis of patients with gliomas, par-
ticularly those with high-grade tumors, remains poor. For
planning the optimal treatment strategy, accurate determi-
nation of tumor grade is critical, and in most histologic
grading systems, vascular proliferation of gliomas is a diag-
nostic criterion for malignancy (1, 17, 21). Although con-
ventional MR imaging with gadolinium-based contrast en-
hancement has been useful for grading gliomas, contrast
enhancement itself reflects disruption of the blood-brain
barrier, not tumor angiogenesis. The area of contrast en-
hancement observed does not indicate the most malignant
portion of the tumor and should not be the only target site
for biopsy (16). 
Perfusion MR imaging methods include the arterial spin-
tagging and the first-pass contrast techniques. The former
does not require the use of contrast material, but is limited
by its sensitivity to motion and low contrast-to-noise ratio
(22), and for these reasons it has not been widely used in
Perfusion MR Imaging in Gliomas
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Fig. 3. Case 19: Low-grade astrocytoma
in a 41-year-old man.
A. Postcontrast T1-weighted image
shows a non-enhancing low signal in-
tensity tumor in the right basal ganglia.
B. Relative cerebral blood volume
(rCBV) map shows low rCBV in the tu-
mor (arrow). 
C. rCBV map shows the placement of
ROIs for measurement of rCBV in the
tumor (small circle) and in contralateral
frontal and occipital white matter (large
circles).
D. Signal intensity-time curves mea-
sured at ROIs in C show less signal re-
duction in this tumor than in the high-
grade gliomas seen in Figs. 1 and 2,
suggesting that the vascularity of an as-
trocytoma is lower. 
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reduction of signal intensity due to local field inhomogene-
ity induced by contrast material within the blood vessels
during the period in which contrast material first passes
through the brain (23). The reduction is proportional to re-
gional CBV and the concentration of contrast material.
Both the spin-echo and gradient-echo techniques can be
utilized for first-pass perfusion imaging. The former is
more sensitive in detecting tumor vascularity at the capil-
lary level (i.e. microvasculature) than at the large vessel
level (5). In contrast, the gradient-echo technique is sensi-
tive to the total volume of blood contained in both capillar-
ies and large vessels (15). Since high-grade gliomas contain
both these types of vessel, the gradient-echo technique is
more suitable for assessing tumor vascularity. Sugahara et
al. (15) reported that the rCBV of gliomas measured by
gradient-echo perfusion imaging correlated well with the
histopathologic and angiographic findings of tumor vascu-
larity. In our study, the rCBV obtained by gradient-echo
perfusion imaging also increased with tumor grade, in ac-
cordance with the demonstrated close correspondence be-
tween rCBV and tumor grade. Since gradient-echo perfu-
sion imaging findings thus reflect tumor vascularity, the
modality can play an important role in the noninvasive de-
termination of which portion of a tumor is most malignant.
The rCBV ratios of gliomas have been described in sev-
eral previous studies. Aronen et al. (5) reported them to be
0.82-5.40 (mean, 3.64) in high-grade gliomas (glioblas-
tomas and anaplastic astrocytomas), and 1.10 1.21 (mean,
1.11) in low-grade gliomas. Sugahara et al. (15) found that
the rCBV ratios of glioblastomas, anaplastic astrocytomas
and low-grade gliomas were 4.00 16.20 (mean, 7.32),
0.98 7.93 (mean, 4.61) and 0.64 2.01 (mean, 1.26), re-
spectively; according to Knopp et al. (16), these ratios were
1.73 13.70 (mean, 5.07) in high-grade gliomas and 0.92
2.19 (mean, 1.44) in low-grade. Although these studies
showed a wide range of rCBV ratios, and overlapping be-
tween tumors of different grades, there were statistically
significantly differences between high-grade and low-grade
gliomas, as in our study. We found that the rCBV ratio cut-
off value which permitted discrimination between high-
grade and low-grade gliomas was 2.60, with 100% sensi-
tivity and 75% specificity. All our results suggest that per-
fusion MR imaging is a valuable technique for assessing the
histologic grade of gliomas. In the clinical field, however, it
should be borne in mind that rCBV ratios may differ ac-
cording to the imaging technique employed (i.e. the imag-
ing sequence, amount of contrast material for bolus injec-
tion, and duration of contrast injection). 
Perfusion MR imaging of gliomas can be used to monitor
response to treatment as well as to determine histologic
grade. Reductions in rCBV have been reported after radia-
tion therapy (24, 25) and during antiangiogenic therapy
(26). rCBV data have also been utilized to distinguish tu-
mor recurrence and non-neoplastic contrast-enhancing tis-
sue after radiation therapy (27), though to ascertain the
usefulness of perfusion MR imaging in this field, further in-
vestigation is needed.
This study suffers from several technical limitations.
First, dynamic contrast-enhanced T2*-weighted imaging
technique can evaluate only a single section rather than a
complete tumor, and this raises concerns about the reliabil-
ity of the data thus obtained. The second limitation is the
relatively low temporal resolution of the imaging, which
provides only a few data points useful for tracking the first
pass of contrast material. These shortcomings could, how-
ever limitations could be mitigated by using the echo-pla-
nar imaging technique, which has become increasingly
available in the clinical field. 
In conclusion, dynamic contrast-enhanced T2*-weighted
perfusion MR imaging performed in these 22 cases provid-
ed valuable information about the vascularity of gliomas,
and led to the correct assessment of histologic tumor grade.
The modality is thus a useful and dependable means of
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Fig. 4. Plot of relative cerebral blood volume (rCBV) ratios in
glioblastomas, anaplastic gliomas and low-grade gliomas. The
rCBV ratio is highest in glioblastomas and lowest in low-grade
gliomas. A comparison of mean rCBV ratios in each tumor group
shows statistically significant differences between them. The dot-
ted horizontal line represents the rCBV ratio cutoff value (2.60)
which permitted discrimination between high-grade (glioblas-
tomas and anaplastic gliomas) and low-grade gliomas. 
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p < .05noninvasively assessing the histologic grade of gliomas.
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